The Week in Review: July 28 – August 4, 2017

Friday, August 4, 2017 Treatment: This last week saw the approval in the U.S. of AbbVie’s Mavyret, a pangenotypic also indicated as recuperation therapy for those with GT1 who have failed treatment with DAAs. U.S.: FDA approves Mavyret for Hepatitis C As well, the FDA has approved updated labeling for Epclusa to include use in patients co-infected with HIV. U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatmen...